French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 6 presentations offering insights into the research and development of ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative ...

Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA ...

Though unexpected CRLs issued by the FDA have caused ripples in the industry, the agency's ex-chief counsel Becky Wood ...

After years of heartbreak, researchers have found an experimental treatment that can slow the progression of Huntington’s ...

We caught up with the team behind the first ever mobile leukapheresis center to see what community-based care could look like ...

Genome editing is increasingly recognized as a leading frontier in biomedical research and an essential driver of healthcare innovation.

Infections particular to our genome may have helped drive human-specific traits — plus, using heat to power DNA computers.

Prime Medicine (NASDAQ:PRME) continues to strengthen its presence in biotechnology and among healthcare stocks. The company’s ...

An update from PepGen Inc. ( ($PEPG) ) is now available. On October 1, 2025, PepGen Inc. updated its corporate presentation, highlighting the ...